ANDROGEN RECEPTORS AND HORMONE SENSITIVITY OF A HUMAN PROSTATIC-CANCER CELL-LINE (PC-3) ARE MODULATED BY NATURAL INTERFERON-BETA

被引:18
作者
SICA, G
DELLACQUA, G
IACOPINO, F
FATTOROSSI, A
MARCHETTI, P
VANDERKWAST, TH
PAVONEMACALUSO, M
机构
[1] DASRS, IMMUNOL LAB, ROME, ITALY
[2] UNIV LAQUILA, DIPARTIMENTO MED SPERIMENTALE ONCOL MED, I-67100 LAQUILA, ITALY
[3] ERASMUS UNIV ROTTERDAM, DEPT PATHOL, 3000 DR ROTTERDAM, NETHERLANDS
[4] UNIV PALERMO, IST CLIN UROL, I-90134 PALERMO, ITALY
来源
UROLOGICAL RESEARCH | 1994年 / 22卷 / 01期
关键词
ANDROGEN RECEPTORS; HORMONE SENSITIVITY; HYDROXYFLUTAMIDE; INTERFERON; PROSTATIC CANCER;
D O I
10.1007/BF00431546
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Androgen receptors are expressed at a low level in the cell line PC-3, which does not respond to either androgens or antiandrogens. If these cells are exposed to natural beta-interferon (beta-IFN) a reduction in cell growth and an increase in androgen receptors, evaluated by both biochemical and immunocytochemical techniques, occur. This increase seems not to be related to a selective block of PC-3 in any phase of the cell cycle. Pretreatment with beta-IFN determines in PC-3 cells a partial responsiveness to the androgen dihydrotestosterone as reflected by the increase in cell number. Moreover, the antiandrogen hydroxyflutamide shows agonistic properties by increasing the cell number of PC-3 cells pre-exposed to beta-IFN. When the antiandrogen is tested in combination with interferon, it produces a reduction in the beta-IFN-induced inhibition of cell growth. It is not known whether these unexpected effects are due to the increase in androgen receptors or to other mechanisms.
引用
收藏
页码:33 / 38
页数:6
相关论文
共 28 条
[1]  
CACCIATORE M, 1990, ACTA UROL ITAL S, V1, P87
[2]   MORPHOMETRY OF INVITRO SYSTEMS - AN IMAGE-ANALYSIS OF 2 HUMAN-PROSTATE CANCER CELL-LINES (PC3 AND DU-145) [J].
CARRUBA, G ;
PAVONE, C ;
PAVONEMACALUSO, M ;
MESITI, M ;
DAQUINO, A ;
VITA, G ;
SICA, G ;
CASTAGNETTA, L .
PATHOLOGY RESEARCH AND PRACTICE, 1989, 185 (05) :704-708
[3]   PROSTATE LONG-TERM EPITHELIAL-CELL LINES - BIOLOGICAL AND BIOCHEMICAL FEATURES [J].
CASTAGNETTA, L ;
CARRUBA, G ;
GRANATA, OM ;
LOCASTO, M ;
ARCURI, F ;
MESITI, M ;
PAVONEMACALUSO, M .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, 595 :149-164
[4]   DNA-SEQUENCE OF THE ANDROGEN RECEPTOR IN PROSTATIC TUMOR-CELL LINES AND TISSUE SPECIMENS ASSESSED BY MEANS OF THE POLYMERASE CHAIN-REACTION [J].
CULIG, Z ;
KLOCKER, H ;
EBERLE, J ;
KASPAR, F ;
HOBISCH, A ;
CRONAUER, MV ;
BARTSCH, G .
PROSTATE, 1993, 22 (01) :11-22
[5]   ANDROGEN RECEPTOR EXPRESSION IN HUMAN TISSUES - AN IMMUNOHISTOCHEMICAL STUDY [J].
DEWINTER, JAR ;
TRAPMAN, J ;
VERMEY, M ;
MULDER, E ;
ZEGERS, ND ;
VANDERKWAST, TH .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1991, 39 (07) :927-936
[6]   APPLICABILITY OF NUCLEAR ANDROGEN RECEPTOR QUANTIFICATION TO HUMAN PROSTATIC ADENOCARCINOMA [J].
FENTIE, DD ;
LAKEY, WH ;
MCBLAIN, WA .
JOURNAL OF UROLOGY, 1986, 135 (01) :167-173
[7]  
GOLDSTEIN D, 1989, CANCER RES, V49, P2698
[8]   RELATIONSHIP BETWEEN CONCENTRATIONS OF EXTRACTABLE AND MATRIX-BOUND NUCLEAR ANDROGEN RECEPTOR AND CLINICAL-RESPONSE TO ENDOCRINE THERAPY FOR PROSTATIC ADENOCARCINOMA [J].
GONOR, SE ;
LAKEY, WH ;
MCBLAIN, WA .
JOURNAL OF UROLOGY, 1984, 131 (06) :1196-1201
[9]  
Hill A. V., 1910, J PHYSL, V40, piv, DOI DOI 10.1113/JPHYSIOL.1910.SP001386
[10]  
JAKESZ R, 1984, CANCER RES, V44, P619